Femasys Inc. (FEMY)
USD 1.08
(-5.26%)
USD 1.08
(-5.26%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 691.9 Thousand USD | -128.27% |
| 2022 | 764.28 Thousand USD | -5.56% |
| 2021 | 809.3 Thousand USD | 10.65% |
| 2020 | 731.38 Thousand USD | 3.69% |
| 2019 | 705.38 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -65.77 Thousand USD | 459.36% |
| 2024 Q1 | -41.28 Thousand USD | 61.53% |
| 2023 Q2 | 210.04 Thousand USD | 11.21% |
| 2023 FY | -216.08 Thousand USD | -128.27% |
| 2023 Q4 | -107.32 Thousand USD | -167.85% |
| 2023 Q3 | 158.17 Thousand USD | -24.69% |
| 2023 Q1 | 188.86 Thousand USD | 26.94% |
| 2022 Q2 | 200.76 Thousand USD | 1.02% |
| 2022 Q1 | 198.73 Thousand USD | 4.59% |
| 2022 Q4 | 148.78 Thousand USD | -31.12% |
| 2022 FY | 764.28 Thousand USD | -5.56% |
| 2022 Q3 | 216 Thousand USD | 7.59% |
| 2021 FY | 809.3 Thousand USD | 10.65% |
| 2021 Q2 | 218.37 Thousand USD | -7.75% |
| 2021 Q4 | 190.01 Thousand USD | 15.74% |
| 2021 Q3 | 164.17 Thousand USD | -24.82% |
| 2021 Q1 | 236.73 Thousand USD | 22.45% |
| 2020 FY | 731.38 Thousand USD | 3.69% |
| 2020 Q1 | 187.32 Thousand USD | 0.0% |
| 2020 Q4 | 193.32 Thousand USD | -13.22% |
| 2020 Q3 | 222.77 Thousand USD | 74.1% |
| 2020 Q2 | 127.95 Thousand USD | -31.69% |
| 2019 FY | 705.38 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 56.3 Million USD | 98.771% |
| AngioDynamics, Inc. | 154.69 Million USD | 99.553% |
| AtriCure, Inc. | 300.37 Million USD | 99.77% |
| Avinger, Inc. | 2 Million USD | 65.457% |
| Azenta, Inc. | 263.14 Million USD | 99.737% |
| BioLife Solutions, Inc. | 46.75 Million USD | 98.52% |
| The Cooper Companies, Inc. | 2.35 Billion USD | 99.971% |
| Daxor Corporation | 1.1 Million USD | 37.296% |
| Ekso Bionics Holdings, Inc. | 9.07 Million USD | 92.379% |
| GlucoTrack, Inc. | -13 Thousand USD | 5422.315% |
| Harvard Bioscience, Inc. | 60.86 Million USD | 98.863% |
| Hologic, Inc. | 2.22 Billion USD | 99.969% |
| ICU Medical, Inc. | 739.87 Million USD | 99.906% |
| Intuitive Surgical, Inc. | 4.72 Billion USD | 99.985% |
| KORU Medical Systems, Inc. | 16.7 Million USD | 95.859% |
| LeMaitre Vascular, Inc. | 127.04 Million USD | 99.455% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 679.826% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 679.826% |
| Masimo Corporation | 1 Billion USD | 99.931% |
| Microbot Medical Inc. | -106 Thousand USD | 752.737% |
| Meihua International Medical Technologies Co., Ltd. | 33.09 Million USD | 97.909% |
| Merit Medical Systems, Inc. | 583.87 Million USD | 99.881% |
| Nephros, Inc. | 8.4 Million USD | 91.768% |
| NovoCure Limited | 381.05 Million USD | 99.818% |
| NEXGEL, Inc. | 619 Thousand USD | -11.777% |
| NEXGEL, Inc. | 619 Thousand USD | -11.777% |
| Singular Genomics Systems, Inc. | -558 Thousand USD | 223.997% |
| OraSure Technologies, Inc. | 179.42 Million USD | 99.614% |
| Pro-Dex, Inc. | 14.55 Million USD | 95.245% |
| Pulse Biosciences, Inc. | -1.2 Million USD | 157.324% |
| Predictive Oncology Inc. | 1.14 Million USD | 39.588% |
| Precision Optics Corporation, Inc. | 5.79 Million USD | 88.066% |
| QuidelOrtho Corporation | 1.49 Billion USD | 99.954% |
| Repligen Corporation | 315.22 Million USD | 99.781% |
| Sanara MedTech Inc. | 57.13 Million USD | 98.789% |
| STAAR Surgical Company | 252.65 Million USD | 99.726% |
| Sharps Technology, Inc. | -891.24 Thousand USD | 177.633% |
| Utah Medical Products, Inc. | 30.03 Million USD | 97.697% |
| DENTSPLY SIRONA Inc. | 2.08 Billion USD | 99.967% |
| Jin Medical International Ltd. | 6.78 Million USD | 89.802% |